Logo

Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China

Share this

Blueprint Medicines Signs an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize BLU-945 and BLU-701 in Greater China

Shots:

  • Blueprint will receive $25M up front, ~$590M in milestones along with royalties on net sales of BLU-945 & BLU-701 in Greater China & will retain all rights to BLU-945 & BLU-701 globally
  • Zai Lab will get the rights to develop & exclusively commercialize BLU-945 & BLU-701 in  Greater China & will lead the development costs for both products
  • The collaboration combines Blueprint's precision therapy expertise with Zai Lab's development capabilities to accelerate the global development of BLU-945 & BLU-701 for NSCLC. Additionally, BLU-945 is currently being evaluated in the P-I/II SYMPHONY trial for EGFR-driven NSCLC & P-I/II trial of BLU-701 is expected to initiate in Q4'21

  Ref: PR Newswire | Image: Blueprint

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions